Á. Rodríguez-Lescure

发表

PAM50 Breast Cancer Subtyping by RT-qPCR and Concordance with Standard Clinical Molecular Markers

Mark T. W. Ebbert, Charles M Perou, Roy R. L. Bastien, 2012, BMC Medical Genomics.

Clinical activity of chronic oral etoposide in previously treated metastatic breast cancer.

J. Garcia-conde, A. Lluch, Á. Rodríguez-Lescure, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Predicting response and survival in chemotherapy-treated triple-negative breast cancer

E Mardis, E. Mardis, C. Fan, 2014, British Journal of Cancer.

Cost-effectiveness analysis of docetaxel (Taxotere®) vs. 5-fluorouracil in combined therapy in the initial phases of breast cancer

Á. Rodríguez-Lescure, M. Ruíz-Borrego, M. Seguí-Palmer, 2009, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Functionally Active Duplications of the CYP2D6 Gene Are More Prevalent among Larynx and Lung Cancer Patients

Julio Benítez, Á. Rodríguez-Lescure, J. Benítez, 2001, Oncology.

PDGFR and IGF-1R Inhibitors Induce a G2/M Arrest and Subsequent Cell Death in Human Glioblastoma Cell Lines

Á. Rodríguez-Lescure, E. Carrasco-García, M. Saceda, 2018, Cells.

Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: results from the GEICAM/2003-02 study.

A. Ruíz, A. Lluch, S. González, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant chemotherapy in young women with breast cancer

Á. Rodríguez-Lescure, 2010, Breast Cancer Research and Treatment.

Adjuvant docetaxel for high-risk, node-negative breast cancer.

A. Ruíz, A. Lluch, J. Zaluski, 2010, The New England journal of medicine.

Evidence-based use of taxanes in the adjuvant setting of breast cancer. A review of randomized phase III trials.

A. Lluch, I. Tusquets, Á. Rodríguez-Lescure, 2007, Cancer treatment reviews.

Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen.

A. Lluch, J. Zaluski, M. Martín, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Influence of cytochrome P450 CYP2C9 genotypes in lung cancer risk.

Á. Rodríguez-Lescure, E. García-Martín, J. Agúndez, 2002, Cancer letters.

Circulating tumour cell analysis as an early marker for relapse in stage II and III colorectal cancer patients: a pilot study

A. Carrato, Á. Rodríguez-Lescure, J. Gallego, 2010, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Overcoming Endocrine Resistance

Á. Rodríguez-Lescure, A. Lluch-Hernández, A. Barnadas, 2016 .

Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2−) early breast cancer (EBC): results from the GEICAM/2006–10 study

A. Guerrero-Zotano, B. Cirauqui, E. Alba, 2019, Breast Cancer Research and Treatment.

The value of sentinel lymph-node biopsy after neoadjuvant therapy: an overview

F. Rojo, A. Lluch, X. Bonfill, 2022, Clinical and Translational Oncology.

Functions and workload of medical oncologists in Spain

J. Albanell, E. Alba, Á. Rodríguez-Lescure, 2012, Clinical and Translational Oncology.

Pilot study on workload estimate in breast cancer, lung cancer and colorectal cancer in a Medical Oncology Service at Valme hospital

J. Albanell, E. Alba, Á. Rodríguez-Lescure, 2012, Clinical and Translational Oncology.

Anti-emetic efficacy of oral granisetron in the total control of late-onset emesis induced by cyclophosphamide-containing chemotherapy

J. Martín-Broto, R. López-López, Á. Rodríguez-Lescure, 2004, Revista de Oncología.

The economic burden of metastatic breast cancer in Spain

Á. Rodríguez-Lescure, M. Ruíz-Borrego, E. Remák, 2018, European journal of hospital pharmacy : science and practice.

Impact of the COVID-19 pandemic on the care of cancer patients in Spain

L. Paz-Ares, X. Matías-Guiu, Á. Rodríguez-Lescure, 2021, ESMO Open.

Defining breast cancer intrinsic subtypes by quantitative receptor expression.

C. Perou, M. Ellis, T. Nielsen, 2015, The oncologist.

Identifying and preventing burnout in young oncologists, an overwhelming challenge in the COVID-19 era: a study of the Spanish Society of Medical Oncology (SEOM)

E. Felip, J. Bosch-Barrera, Á. Rodríguez-Lescure, 2021, ESMO Open.

Bone loss induced by cancer treatments in breast and prostate cancer patients

Á. Rodríguez-Lescure, S. Castañeda, X. Nogués, 2022, Clinical and Translational Oncology.

Multicenter, randomized phase III study of adjuvant chemotherapy for high-risk, node-negative breast cancer comparing tac with fac: 5-year efficacy analysis of the GEICAM 9805 trial

M. Martín, M. Ramos, Á. Rodríguez-Lescure, 2008 .

Regional and seasonal influence in patient’s toxicity to adjuvant chemotherapy for early breast cancer

A. Ruíz, E. Alba, E. Carrasco, 2010, Breast Cancer Research and Treatment.

Increased risk for hepatocellular carcinoma in NAT2-slow acetylators and CYP2D6-rapid metabolizers.

U. Meyer, Á. Rodríguez-Lescure, M. Díaz‐Rubio, 1996, Pharmacogenetics.

A retrospective, multicenter study of the efficacy of lapatinib plus trastuzumab in HER2-positive metastatic breast cancer patients previously treated with trastuzumab, lapatinib, or both: the Trastyvere study

J. Brunet, A. Guerrero-Zotano, A. Llombart-Cussac, 2020, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Multidisciplinary consensus on the criteria for fertility preservation in cancer patients

C. Márquez-Vega, L. Bassas, Á. Rodríguez-Lescure, 2021, Clinical and Translational Oncology.

Bone loss induced by cancer treatments in breast and prostate cancer patients

Á. Rodríguez-Lescure, S. Castañeda, X. Nogués, 2022, Clinical and Translational Oncology.

The value of sentinel lymph-node biopsy after neoadjuvant therapy: an overview

F. Rojo, A. Lluch, X. Bonfill, 2022, Clinical and Translational Oncology.

Bone loss induced by cancer treatments in breast and prostate cancer patients

Á. Rodríguez-Lescure, S. Castañeda, X. Nogués, 2022, Clinical and Translational Oncology.

Maintenance treatment with Pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001-01 study

A. Ruíz, M. Margelí, E. Alba, 2010, Breast Cancer Research and Treatment.

The value of sentinel lymph-node biopsy in women with node-positive breast cancer at diagnosis and node-negative tumour after neoadjuvant therapy: a systematic review

F. Rojo, A. Lluch, X. Bonfill, 2022, Clinical and Translational Oncology.

Bevacizumab in advanced breast cancer: a new model for the assessment of activity in non-first-line treatment regimens

D. Torrejon, E. Alba, Á. Rodríguez-Lescure, 2013, Anti-cancer drugs.

2019 SEOM guidelines (the end of a decade)

Á. Rodríguez-Lescure, A. González-del-Alba, 2020, Clinical and Translational Oncology.

Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01)

H. Gómez, A. Guerrero-Zotano, A. Lluch, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.

Arrate Plazaola, Emilio Alba, Carmen Crespo, 2008, Journal of the National Cancer Institute.

Toxicity and health-related quality of life (HRQoL) in node-negative breast cancer (BC) patients (pts) receiving adjuvant treatment with TAC (docetaxel, doxorubicin, cyclophosphamide) or FAC (5-fluorouracil, doxorubicin, cyclophosphamide): Impact of adding prophylactic growth factors (GF) to TAC. GE

A. Lluch, M. Martín, M. Ramos, 2005 .

PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer

Donald A. Berry, Mark T. W. Ebbert, Charles M. Perou, 2013, Breast Cancer Research and Treatment.

CYP2D6 genes and risk of liver cancer

Á. Rodríguez-Lescure, M. Díaz‐Rubio, E. Díaz-Rubio, 1995, The Lancet.

Prophylactic growth factor (GF) support with adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-negative breast cancer (BC): An interim safety analysis of the GEICAM 9805 study.

A. Lluch, M. Martín, M. Ramos, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Acute and anticipatory emesis in breast cancer patients

Á. Rodríguez-Lescure, J. Sanchez, E. Díaz-Rubio, 1996, Supportive Care in Cancer.

Subgroup analysis of GEICAM 9906 trial comparing six cycles of FE90C (FEC) to four cycles of FE90C followed by 8 weekly paclitaxel administrations (FECP): Relevance of HER2 and hormonal status (HR)

E. Álava, A. Ruíz, A. Cruz, 2007 .

Adjuvant docetaxel for node-positive breast cancer.

Marek Pawlicki, John Hainsworth, Matthieu Rupin, 2005, The New England journal of medicine.

CLytA-DAAO Chimeric Enzyme Bound to Magnetic Nanoparticles. A New Therapeutical Approach for Cancer Patients?

C. de Juan Romero, Á. Rodríguez-Lescure, J. Sanz, 2021, International journal of molecular sciences.

Dual neoadjuvant blockade plus chemotherapy versus monotherapy for the treatment of women with non-metastatic HER2-positive breast cancer: a systematic review and meta-analysis

A. Lluch, X. Bonfill, S. Servitja, 2022, Clinical and Translational Oncology.

Quantitative hormone receptors, triple-negative breast cancer (TNBC), and molecular subtypes: A collaborative effort of the BIG-NCI NABCG.

C. Perou, M. Ellis, T. Nielsen, 2012 .

Lack of cytomegalovirus detection in human glioma

Á. Rodríguez-Lescure, Enrique Ochoa, A. García-Martínez, 2017, Virology Journal.

Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysis

J. Mackey, A. Lluch, O. Trédan, 2013, Breast Cancer Research.

Multidisciplinary consensus on cancer management during pregnancy

Á. Rodríguez-Lescure, E. Goñi, F. Matute, 2020, Clinical and Translational Oncology.

A snapshot of cancer-associated thromboembolic disease in 2018-2019: First data from the TESEO prospective registry.

Á. Rodríguez-Lescure, P. Jiménez-Fonseca, A. Muñoz, 2020, European journal of internal medicine.

Prognostic role for the derived neutrophil-to-lymphocyte ratio in early breast cancer: a GEICAM/9906 substudy

A. Lluch, E. Alba, M. Martín, 2018, Clinical and Translational Oncology.

Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

F. Rojo, E. de Álava, J. Rodríguez-Peralto, 2019, Clinical and Translational Oncology.

Diagnosis and medical treatment of breast cancer. Cordoba Consensus of 2007

A. Lluch, E. Alba, Á. Rodríguez-Lescure, 2008, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER).

A. Molassiotis, M. Aapro, P. Gascón, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II trial with letrozole to maximum response as primary systemic therapy in postmenopausal patients with ER/PgR[+] operable breast cancer

A. Ruíz, A. Llombart-Cussac, V. Carañana, 2012, Clinical and Translational Oncology.

Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2− breast cancer patients: results from the GEICAM 9906 trial

K. Weber, A. Ruíz, E. Alba, 2014, Breast Cancer Research.

Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone

J. Cuzick, W. Gradishar, M. Gnant, 2019, Breast Cancer Research and Treatment.

Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer

E. Álava, A. Ruíz, E. Alba, 2010, Breast Cancer Research and Treatment.

Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study

C. Perou, P. Bernard, K. Weber, 2016, Breast Cancer Research and Treatment.

Differential Effects of IGF-1R Small Molecule Tyrosine Kinase Inhibitors BMS-754807 and OSI-906 on Human Cancer Cell Lines

J. Encinar, Á. Rodríguez-Lescure, J. Martín-Nieto, 2020, Cancers.

RsaI polymorphism at the cytochrome P4502E1 locus and risk of hepatocellular carcinoma.

Á. Rodríguez-Lescure, M. Díaz‐Rubio, J. Benítez, 1996, Gut.

Adjuvant Docetaxel plus Doxorubicin and Cyclophosphamide for Node-Positive Breast Cancer

A. Howell, J. Hainsworth, J. Mackey, 2005 .

Epirubicin-cyclophosphamide adjuvant chemotherapy plus tamoxifen administered concurrently versus sequentially: randomized phase III trial in postmenopausal node-positive breast cancer patients. A GEICAM 9401 study.

A. Tres, E. Alba, M. Martín, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

N-acetyltransferase 2 single-nucleotide polymorphisms and risk of gastric carcinoma

Á. Rodríguez-Lescure, M. Díaz‐Rubio, J. Benítez, 2002, European Journal of Clinical Pharmacology.

The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER).

A. Molassiotis, M. Aapro, P. Gascón, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Impact of the COVID-19 pandemic on the diagnosis and treatment of onco-hematologic patients: a discussion paper

V. Guillem, V. Jiménez‐Yuste, Á. Rodríguez-Lescure, 2022, Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia.

High-dose DICEP chemotherapy versus observation in metastatic breast cancer patients with monotopic disease responding to induction chemotherapy with paclitaxel plus epirubicin. Final results of a phase III GEICAM trial

E. Alba, Á. Rodríguez-Lescure, Miguel Martín, 2003, Revista de Oncología.

Phase I/II study of biweekly vinorelbine and oxaliplatin as first-line treatment in patients with metastatic breast cancer

S. Servitja, I. Tusquets, L. Calvo, 2011, Anti-cancer drugs.

An Overview of Letrozole in Postmenopausal Women with Hormone-Responsive Breast Cancer

Á. Rodríguez-Lescure, A. Barnadas, P. Sánchez‐Rovira, 2011, Advances in therapy.

Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial.

J. Hainsworth, J. Mackey, D. Walde, 2013, The Lancet. Oncology.

Prolongation of TTP by maintenance therapy with PLD in a multicenter phase III randomized trial following standard chemotherapy for MBC: GEICAM 2001-01 study

M. Margelí, E. Alba, N. Ribelles, 2007 .

Prednimustine-induced myoclonus--a report of three cases.

Á. Rodríguez-Lescure, J. López-Martín, E. Díaz-Rubio, 1994, Acta oncologica.

Weekly continuous infusion of 5-fluorouracil with oral leucovorin in metastatic breast cancer patients with primary resistance to doxorubicin

Y. Nieto, Á. Rodríguez-Lescure, Miguel Martín, 1998, Breast Cancer Research and Treatment.

The use of taxanes in the neoadjuvant treatment of breast cancer: a review of randomized phase II/III trials.

J. Albanell, A. Lluch, I. Tusquets, 2007, Clinical breast cancer.

Advanced breast cancer clinical nursing curriculum: review and recommendations

Á. Rodríguez-Lescure, M. Muñoz, R. Colomer, 2016, Clinical and Translational Oncology.

A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer

P. Jares, A. Lluch, A. Urruticoechea, 2019, Front. Oncol..

Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study.

A. Lluch, S. González, R. Andrés, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Future care for long-term cancer survivors: towards a new model

M. Provencio, Á. Rodríguez-Lescure, P. Garrido, 2021, Clinical and Translational Oncology.

Assessment of a Genomic Assay in Patients With ERBB2-Positive Breast Cancer Following Neoadjuvant Trastuzumab-Based Chemotherapy With or Without Pertuzumab.

C. Perou, J. Parker, E. Mittendorf, 2023, JAMA oncology.

Re-interpretation of PAM50 gene expression as quantitative tumor dimensions shows utility for clinical trials: application to prognosis and response to paclitaxel in breast cancer

N. Camp, J. Herranz, P. Bernard, 2019, Breast Cancer Research and Treatment.

Multicenter, randomized phase III study of adjuvant chemotherapy for axillary positive breast cancer (APBC) comparing 6 cycles (cy) of FEC vs 4 cy of FEC followed by 8 weekly paclitaxel (T) administrations: Safety analysis of GEICAM 9906 trial.

A. Ruíz, E. Alba, B. Munárriz, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Study of the Spanish Society of Medical Oncology (SEOM) on the access to oncology drugs and predictive biomarkers in Spain

E. Felip, Á. Rodríguez-Lescure, P. Garrido, 2020, Clinical and Translational Oncology.

P128 Phase II trial with letrozole (2.8 mg) to maximal response as neoadjuvant endocrine therapy in postmenopausal patients with ER/PgR[+] operable breast cancer

A. Ruíz, C. Vázquez, V. Carañana, 2007 .

Medical oncology workload, workforce census, and needs in Spain: two nationwide studies by the Spanish Society of medical oncology

E. Felip, Á. Rodríguez-Lescure, D. Páez, 2023, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Breast cancer, locally advanced and metastatic

L. Holmberg, O. Nanni, S. Barni, 2012 .

Impact of the COVID-19 pandemic on the care of cancer patients in Spain

X. Matías-Guiu, Á. Rodríguez-Lescure, J. C. de la Torre-Montero, 2021, ESMO Open.

Recurrent pericardial effusion as initial manifestation of primary diffuse pericardial malignant mesothelioma

Á. Rodríguez-Lescure, C. G. Ponce, M. Garrido, 2006, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

RsaIpolymorphism atthecytochrome P4502E1 locus andrisk ofhepatocellular carcinoma

Á. Rodríguez-Lescure, J. Ladero, 1996 .

Adjuvant dabrafenib and trametinib for patients with resected BRAF-mutated melanoma: DESCRIBE-AD real-world retrospective observational study

E. Espinosa, L. Fernández-Morales, Á. Rodríguez-Lescure, 2023, Melanoma research.

Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: results from the GEICAM/2003-02 study.

A. Ruíz, A. Lluch, S. González, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.

J. Mayordomo, A. Ruíz, A. Lluch, 2008, Journal of the National Cancer Institute.